Hyderabad: Even as loss of contract production orders, hike in energy costs, rising inflation and mounting debts have impacted the Indian pharma industry, Biocon has said that the “regulatory underst

Pharma major Cipla Ltd plans to invest Rs 500 crore for setting up an active pharmaceutical ingredients (API) facilities at Patalganga, Bengaluru and Kurkumbh.

The setting up of these facilities

Indian government has put in place a $5.4 billion policy to provide free medicine to its people, a decision that could change the lives of hundreds of millions, but a ban on branded drugs stands to cu

The patent expiry of several major 'blockbuster' drugs, coupled with other factors, will fuel growth of global generic pharmaceuticals market by 2017, research firm Frost & Sullivan said.

"Immi

The Indian generic drug industry is generally receptive to the proposed US law on medicine even though it seeks to enhance US-FDA inspection of the manufacturing facilities globally for a fee.

Indus

Leading pharma companies including GlaxoSmithkline, Pfizer and Ranbaxy sell commonly used drugs at a rate 10 times the cost of production, a study by the Corporate Affairs Ministry has found.

A st

The growth rate for the domestic Indian pharmaceutical market is set to rise over medium-term, according to a research report.

The revenue CAGR (compound annual growth rate) over the past three year

In a decision that could lead to cheaper drugs, the Indian Patent Office has invoked a provision in the WTO’s TRIPS agreement to allow Hyderabad-based Natco Pharma Ltd to manufacture and sell a generi